Show simple item record

dc.contributor.authorde Boer, S
dc.contributor.authorPowell, M
dc.contributor.authorMileshkin, L
dc.contributor.authorKatsaros, D
dc.contributor.authorBessette, P
dc.contributor.authorHaie-Meder, C
dc.contributor.authorOttevanger, P
dc.contributor.authorLedermann, J
dc.contributor.authorKhaw, P
dc.contributor.authorColombo, A
dc.contributor.authorFyles, A
dc.contributor.authorBaron, M
dc.contributor.authorJürgenliemk-Schulz, I
dc.contributor.authorKitchener, Henry C
dc.contributor.authorNijman, H
dc.contributor.authorWilson, G
dc.contributor.authorBrooks, S
dc.contributor.authorCarinelli, S
dc.contributor.authorProvencher, D
dc.contributor.authorHanzen, C
dc.contributor.authorLutgens, L
dc.contributor.authorSmit, V
dc.contributor.authorSingh, N
dc.contributor.authorDo, V
dc.contributor.authorD'Amico, R
dc.contributor.authorNout, R
dc.contributor.authorFeeney, A
dc.contributor.authorVerhoeven-Adema, KW
dc.contributor.authorPutter, H
dc.contributor.authorCreutzberg, C
dc.date.accessioned2018-03-27T14:28:35Z
dc.date.available2018-03-27T14:28:35Z
dc.date.issued2018-03
dc.identifier.citationAdjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. 2018, 19 (3):295-309 Lancet Oncol.en
dc.identifier.issn1474-5488
dc.identifier.pmid29449189
dc.identifier.doi10.1016/S1470-2045(18)30079-2
dc.identifier.urihttp://hdl.handle.net/10541/620870
dc.description.abstractAlthough women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleAdjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands.en
dc.identifier.journalThe Lancet. Oncologyen
refterms.dateFOA2019-09-21T20:09:28Z
html.description.abstractAlthough women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.


Files in this item

Thumbnail
Name:
PIIS147020451930395X.pdf
Size:
417.8Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record